Abbvie Inc
XBER:4AB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Abbvie Inc
XBER:4AB
|
US |
|
C
|
Coca-Cola Europacific Partners PLC
F:CK0
|
UK |
|
Mitsubishi Corp
TSE:8058
|
JP |
|
T
|
TUI AG
SWB:TUI1
|
DE |
|
N
|
Netflix Inc
SWB:NFC
|
US |
|
SI-BONE Inc
NASDAQ:SIBN
|
US |
|
E
|
Endurance Technologies Ltd
BSE:540153
|
IN |
Abbvie Inc
AbbVie is a pharmaceutical company that develops and sells prescription medicines. Its business is built around branded drugs for conditions such as immune disorders, cancer, eye disease, and other serious illnesses. It also works on research and development to create new treatments and support its long-term drug portfolio. The company makes money mainly by selling medicines to wholesalers, pharmacies, hospitals, and other healthcare providers, which then reach patients. In some areas it also earns income from licensing and collaboration deals tied to its drug research and development. Because its products are prescription therapies, AbbVie depends on physician adoption, regulatory approval, and patent protection more than on consumer branding. AbbVie’s role in the healthcare system is that of a maker of specialized, high-value medicines rather than a broad medical supplier. It focuses on drugs that address chronic or complex diseases, where patients often need long-term treatment. That gives the company a business model centered on patented products, clinical research, and close ties to the pharmaceutical supply chain.
AbbVie is a pharmaceutical company that develops and sells prescription medicines. Its business is built around branded drugs for conditions such as immune disorders, cancer, eye disease, and other serious illnesses. It also works on research and development to create new treatments and support its long-term drug portfolio.
The company makes money mainly by selling medicines to wholesalers, pharmacies, hospitals, and other healthcare providers, which then reach patients. In some areas it also earns income from licensing and collaboration deals tied to its drug research and development. Because its products are prescription therapies, AbbVie depends on physician adoption, regulatory approval, and patent protection more than on consumer branding.
AbbVie’s role in the healthcare system is that of a maker of specialized, high-value medicines rather than a broad medical supplier. It focuses on drugs that address chronic or complex diseases, where patients often need long-term treatment. That gives the company a business model centered on patented products, clinical research, and close ties to the pharmaceutical supply chain.
Beat and raise: AbbVie beat first-quarter expectations across the board, with adjusted EPS of $2.65, revenue of $15 billion, and management raising full-year EPS guidance to $14.08 to $14.28.
Immunology strength: Skyrizi and Rinvoq both outperformed, while Humira continued to decline as expected. Management said Skyrizi and Rinvoq remain the key growth engines and still have room to run.
Pipeline momentum: The company highlighted encouraging late-stage data in Crohn's disease, progress in alopecia areata, HS, Parkinson's, oncology, and obesity, plus earlier-than-expected oncology filing plans.
Capital plans: AbbVie reiterated it has ample financial capacity for business development and is continuing major U.S. manufacturing and R&D investment, including new North Carolina and North Chicago sites.
Competition outlook: Management said it is prepared for new competition in immunology and aesthetics, and believes its products’ efficacy, durability, and label breadth should help defend share.
Aesthetics softer: Botox Cosmetic grew well, but the broader aesthetics market remained pressured by consumer headwinds, especially for fillers like Juvederm.
Management
Richard A. Gonzalez is the Chairman and Chief Executive Officer of AbbVie Inc., a research-driven biopharmaceutical company. He has played a pivotal role in guiding AbbVie since its inception as a spin-off from Abbott Laboratories in 2013. Gonzalez has a long history with Abbott Laboratories, having held various leadership positions. He served as Abbott's Executive Vice President of the Pharmaceutical Products Group, where he was responsible for the company's global pharmaceuticals business. Gonzalez joined Abbott in 1977 and has a broad range of experience across several divisions within the company. His leadership at AbbVie has been marked by a strong focus on innovation and strategic acquisitions to enhance the company's product pipeline. Under his guidance, AbbVie has developed and marketed several key products, particularly in the areas of immunology and oncology. Gonzalez holds a strong commitment to addressing unmet medical needs and improving patient outcomes, solidifying AbbVie's position as a leading biopharmaceutical company globally. His leadership style emphasizes scientific excellence, patient-centered strategies, and fostering a strong company culture.
Gonzalez joined Abbott in 1977 and has a broad range of experience across several divisions within the company. His leadership at AbbVie has been marked by a strong focus on innovation and strategic acquisitions to enhance the company's product pipeline. Under his guidance, AbbVie has developed and marketed several key products, particularly in the areas of immunology and oncology.
Gonzalez holds a strong commitment to addressing unmet medical needs and improving patient outcomes, solidifying AbbVie's position as a leading biopharmaceutical company globally. His leadership style emphasizes scientific excellence, patient-centered strategies, and fostering a strong company culture.
Robert A. Michael is a notable executive at AbbVie Inc., a leading global biopharmaceutical company. As part of AbbVie’s leadership team, Michael has played a significant role in guiding the company's strategic, financial, and operational direction. Robert A. Michael has served as President and Vice Chairman of AbbVie, overseeing various critical aspects of the business. Before this, he was AbbVie's Chief Financial Officer, where he was responsible for the financial operations of the company, including financial planning, analysis, and investor relations. His leadership in financial strategy has been instrumental in supporting AbbVie's growth and innovation in the pharmaceutical sector. Before joining AbbVie, Robert Michael held multiple leadership roles within Abbott Laboratories, which AbbVie was spun off from in 2013. His extensive experience in the pharmaceutical industry and financial management has made him a key figure in AbbVie’s continued success and expansion in the global market. His academic background includes a degree in economics from the University of Michigan and an MBA from the University of Chicago, ensuring a strong foundation for his career in finance and executive management.
Robert A. Michael has served as President and Vice Chairman of AbbVie, overseeing various critical aspects of the business. Before this, he was AbbVie's Chief Financial Officer, where he was responsible for the financial operations of the company, including financial planning, analysis, and investor relations. His leadership in financial strategy has been instrumental in supporting AbbVie's growth and innovation in the pharmaceutical sector.
Before joining AbbVie, Robert Michael held multiple leadership roles within Abbott Laboratories, which AbbVie was spun off from in 2013. His extensive experience in the pharmaceutical industry and financial management has made him a key figure in AbbVie’s continued success and expansion in the global market.
His academic background includes a degree in economics from the University of Michigan and an MBA from the University of Chicago, ensuring a strong foundation for his career in finance and executive management.
Scott T. Reents currently serves as Senior Vice President, President of Financial Operations, and Chief Financial Officer at AbbVie Inc. In these roles, he is responsible for overseeing the global financial operations of the company, including treasury, tax, investor relations, and information technology. Reents brings a wealth of experience in financial management and strategic planning to his position, contributing to AbbVie's financial health and strategic growth. Before joining AbbVie, he held various leadership positions in finance at major pharmaceutical companies, where he honed his expertise in driving financial performance and developing innovative financial strategies. His leadership is key to AbbVie's ongoing success in the highly competitive biopharmaceutical industry.
Dr. Azita Saleki-Gerhardt is a notable figure in the pharmaceutical industry, currently serving as an executive at AbbVie Inc., where she plays a significant role in the company's operations. She joined Abbott, the precursor to AbbVie, in 1993 as a research scientist and has since held various leadership roles across pharmaceutical development and manufacturing. Dr. Saleki-Gerhardt earned her Bachelor of Science, Master of Science, and Ph.D. degrees in Pharmaceutics and Drug Delivery from the University of Wisconsin-Madison. Her extensive academic background in pharmaceutics has contributed to her influential career in pharmaceutical sciences and global manufacturing operations. At AbbVie, Dr. Saleki-Gerhardt has been integral in overseeing global supply chain operations, driving process improvements, and ensuring the effective supply of pharmaceutical products worldwide. She is recognized for her strategic insight and leadership in advancing AbbVie’s global manufacturing network, which includes plants in several countries around the world. Her work has been instrumental in enhancing efficiency and innovation in AbbVie's production processes. Furthermore, she is involved in various industry initiatives and associations, further highlighting her commitment to advancing the pharmaceutical sector.
Dr. Saleki-Gerhardt earned her Bachelor of Science, Master of Science, and Ph.D. degrees in Pharmaceutics and Drug Delivery from the University of Wisconsin-Madison. Her extensive academic background in pharmaceutics has contributed to her influential career in pharmaceutical sciences and global manufacturing operations.
At AbbVie, Dr. Saleki-Gerhardt has been integral in overseeing global supply chain operations, driving process improvements, and ensuring the effective supply of pharmaceutical products worldwide. She is recognized for her strategic insight and leadership in advancing AbbVie’s global manufacturing network, which includes plants in several countries around the world. Her work has been instrumental in enhancing efficiency and innovation in AbbVie's production processes. Furthermore, she is involved in various industry initiatives and associations, further highlighting her commitment to advancing the pharmaceutical sector.
Jeffrey Ryan Stewart currently serves as the Chief Commercial Officer at AbbVie Inc., a position he has held since his appointment in 2018. With a Bachelor of Science degree from the University of Southern California and a Master of Business Administration from the University of Pennsylvania's Wharton School, Stewart brings a robust educational background to his role. Before joining AbbVie, he had an extensive career at Abbott Laboratories in various leadership roles, contributing significantly to the company's commercial and strategic development initiatives. At AbbVie, Stewart is responsible for overseeing the company’s commercial operations globally, playing a crucial role in driving sales, marketing, and global market access strategies. His leadership is vital in ensuring that AbbVie’s therapeutic solutions reach patients worldwide, enhancing the company’s mission of addressing the world's pressing healthcare challenges.
Dr. Roopal Thakkar, M.D., serves as a prominent executive at AbbVie Inc., where he holds the position of Senior Vice President and Chief Medical Officer. He plays a crucial role in steering the company’s global medical and regulatory strategies. With a vast experience in the pharmaceutical industry, Dr. Thakkar is instrumental in overseeing clinical development and the advancement of the company's pipeline across various therapeutic areas. His leadership ensures that AbbVie's products meet rigorous standards for safety and efficacy, ultimately impacting patient care and treatment solutions globally. His expertise and strategic vision contribute significantly to AbbVie’s mission of developing innovative healthcare solutions.
Elizabeth Shea serves as the Vice President and Corporate Secretary at AbbVie Inc., a global biopharmaceutical company. In her role, she is integral to AbbVie's governance, providing advice and support to the company's Board of Directors and senior management. With a robust legal background, Shea oversees compliance with corporate governance standards and manages the documentation of board activities, ensuring transparency and adherence to legal and regulatory requirements. She plays a key role in shareholder relations, contributing to AbbVie's commitment to ethical business practices and strategic growth. Her expertise is vital in navigating the complex landscape of the pharmaceutical industry.
Perry C. Siatis is a notable executive with extensive legal expertise who has held significant roles at AbbVie Inc., a global biopharmaceutical company. He serves as the Executive Vice President, General Counsel, and Secretary at AbbVie. Siatis is responsible for overseeing the company’s global legal activities, providing strategic guidance on legal matters, regulatory issues, and corporate governance. Before joining AbbVie, Perry C. Siatis gained significant experience at Abbott Laboratories, where he had been part of the legal team, contributing to various roles that involved corporate legal affairs, litigation, and compliance. His legal acumen and strategic insight have been critical in navigating the complex regulatory environment of the pharmaceutical industry. Siatis holds a juris doctor degree and has a strong foundation in legal and compliance matters, which has been instrumental in his leadership at AbbVie. His contributions to AbbVie have been significant in supporting the company’s strategic goals, ensuring legal compliance, and safeguarding its interests as it pursues innovative medical solutions.
Before joining AbbVie, Perry C. Siatis gained significant experience at Abbott Laboratories, where he had been part of the legal team, contributing to various roles that involved corporate legal affairs, litigation, and compliance. His legal acumen and strategic insight have been critical in navigating the complex regulatory environment of the pharmaceutical industry. Siatis holds a juris doctor degree and has a strong foundation in legal and compliance matters, which has been instrumental in his leadership at AbbVie.
His contributions to AbbVie have been significant in supporting the company’s strategic goals, ensuring legal compliance, and safeguarding its interests as it pursues innovative medical solutions.
Timothy J. Richmond is recognized for his role as Executive Vice President and Chief Human Resources Officer at AbbVie Inc., a leading global biopharmaceutical company. Richmond has been instrumental in shaping the company's human resources strategies, emphasizing talent development, organizational culture, and employee engagement. His leadership has focused on fostering an inclusive and dynamic work environment that aligns with AbbVie's mission to address the world's critical health challenges. Richmond joined AbbVie at its inception in 2013, following its separation from Abbott Laboratories, where he also held various senior HR roles. His extensive experience in human resources has been pivotal in supporting the company's rapid growth and global operations. Under his guidance, AbbVie has been recognized for its workplace culture and commitment to diversity and inclusion. With a strong educational background, including a degree in political science and an MBA, Richmond applies a strategic approach to human resources, ensuring that the company's people strategies effectively support its business objectives. His contributions have been vital in maintaining AbbVie's status as an employer of choice in the competitive pharmaceutical industry.
Richmond joined AbbVie at its inception in 2013, following its separation from Abbott Laboratories, where he also held various senior HR roles. His extensive experience in human resources has been pivotal in supporting the company's rapid growth and global operations. Under his guidance, AbbVie has been recognized for its workplace culture and commitment to diversity and inclusion.
With a strong educational background, including a degree in political science and an MBA, Richmond applies a strategic approach to human resources, ensuring that the company's people strategies effectively support its business objectives. His contributions have been vital in maintaining AbbVie's status as an employer of choice in the competitive pharmaceutical industry.
